Effect of negatively charged liposomes on ADP-induced platelet aggregation

Zakrevskii, V. I.; Rud'ko, I. A.; Кубатиев, Аслан Амирханович

doi:10.1007/bf00837645

Cited by 2 publications

(3 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been demonstrated that liposomes are able to induce (119)(120)(121) as well as inhibit (122,123) aggregation of platelets. The types of phospholipids in the membrane of the liposomes (124)(125)(126) and the surface charge of these vesicles (119)(120)(121)(122)(123) seem to play a role in the procoagulatory properties. Platelet aggregation in vitro and rat thrombosis in vivo was reported to be induced by carbon nanoparticles (127), whereas neutral and PEG-coated surfactant-based nanoparticles did not induce platelet activation in vitro (128).…”

Section: Platelet Activationmentioning

confidence: 99%

“…Platelet aggregation in vitro and rat thrombosis in vivo was reported to be induced by carbon nanoparticles (127), whereas neutral and PEG-coated surfactant-based nanoparticles did not induce platelet activation in vitro (128). Liposomes with a negative surface charge have been reported to increase as well as inhibit platelet aggregation (120)(121)(122)(123).…”

Section: Platelet Activationmentioning

confidence: 99%

See 1 more Smart Citation

Immunological Risk of Injectable Drug Delivery Systems

et al. 2009

View full text Add to dashboard Cite

Abstract. Injectable drug delivery systems (DDS) such as particulate carriers and water-soluble polymers are being used and developed for a wide variety of therapeutic applications. However, a number of immunological risks with serious clinical implications are associated with administration of DDS. These immunological events can compromise the efficacy and safety of these systems by changing the pharmacokinetics, biodistribution and targeting capability of DDS, and by inducing hypersensitivity reactions. Antibodies induced by administration of DDS can be directed against the carrier material, the drug and/or targeting ligands associated with the DDS. Complement activation and opsonization of DDS, which may or may not be associated with antibody formation, may lead to accelerated clearance, hypersensitivity reactions and formation of membrane attack complexes resulting in premature release of the drug. Also platelets have been reported to play a role in DDS immunogenicity. Despite our curtailed understanding of the relationships between physicochemical characteristics and immunogenicity of DDS, several risk factors have been identified. Insight into these factors should be employed in the development of novel DDS with low immunological risk.

show abstract

Section: Platelet Activationmentioning

confidence: 99%

Section: Platelet Activationmentioning

confidence: 99%

Immunological Risk of Injectable Drug Delivery Systems

et al. 2009

View full text Add to dashboard Cite

show abstract

“…Plasma lipids are a variable chemical component that modulates functional activity of platelets; the state of plasma lipids strongly depends on the intensity of peroxidative processes [2,6]. However, intensification of lipid peroxidation (LPO) is a pathogenic factor provoking nlolecular and cellular interactions which underlie homeostatic perturbations.…”

mentioning

confidence: 99%